Roche comes out against allowing takeover of drug manufacturer Catalent
Adds comment from Novo Holdings in paragraph 13
Roche CEO: not good to limit competition in this space
Roche says not itself, but others affected by Catalent deal
Swiss drugmaker joins US peer Lilly in voicing opposition
Eli Lilly and advocacy groups also voice concerns over the deal
Novo Nordisk and Catalent defend the acquisition, citing ample competition
By Ludwig Burger
FRANKFURT, Oct 23 (Reuters) -The CEO of pharmaceuticals giant Roche ROG.S said authorities should block the takeover of contract drug manufacturer Catalent CTLT.N by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Though it stressed on Wednesday it was not itself affected, Roche is among the first drugmakers to voice opposition to the transaction with potentially wide-ranging repercussions for weight-loss drugs based on the gut hormone GLP-1.
"Limiting the competition in this space is not a good idea," Roche's CEO Thomas Schinecker said in a media call. "From an industry perspective, it would be a wrong decision by authorities."
"It could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available," he told journalists, speaking after the release of quarterly sales on Wednesday.
The company said it would not comment further on any interactions with competition authorities.
"In general, if companies start buying up CMOs (contract manufacturing organisations), that will limit the amount of competition that there can be," Schinecker added in a later analyst call.
Last week, an alliance of U.S. consumer, patient and workers advocacy groups petitioned the U.S. Federal Trade Commission to block Novo Holdings, which controls Novo Nordisk NOVOb.CO, from acquiring Catalent, saying the deal threatened competition in weight loss drugs and gene therapies.
Executives at Eli Lilly LLY.N, Novo's main rival in the obesity and diabetes drug market, have repeatedly voiced concerns over the transaction, which will also see Novo Nordisk take direct ownership of three Catalent sites where injection pens are filled in Italy, Belgium and the United States.
The advocacy groups said at the time that the deal could constrain competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche and AstraZeneca AZN.L, which are reportedly developing their own obesity drugs, some of which are based on difficult-to-make peptides.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS could also be affected, the advocacy groups said.
A Novo Nordisk spokesperson, commenting on the Roche CEO's remarks, said: "If the acquisition is approved, Novo Nordisk will purchase three manufacturing sites from Novo Holdings. Catalent will still operate close to 50 sites independently and separate from Novo Nordisk."
The Novo Nordisk spokesperson said that a "large number" of other contract drugmakers compete with Catalent and said that, if the acquisition is approved, pharma and biotech companies "will continue to have access to ample choice for contract manufacturing, including Catalent." The spokesperson reiterated the company's expectation that the transaction will close towards the end of this year.
Novo Holdings said Catalent would continue to operate independently as a leading contract drug manufacturer.
Catalent said: "We are confident that the transaction is pro-competitive, and we are unaware of any competitive GLP-1 products being manufactured for commercial sale at the three sites that Novo Nordisk is planning to acquire."
It added it would continue to work closely with European and U.S. regulators and that it still expected the transaction to close towards the end of 2024.
Novo would not be the first pharma major to run contract manufacturing operations serving rivals, as Pfizer PFE.N and Boehringer Ingelheim, for example, also own such divisions.
The head of Roche's pharmaceutical division, Teresa Graham, underscored on Wednesday that Roche itself was not impacted: "We are quite confident in the capacity we have. We have reserved capacity with other CMOs."
When asked last week to comment on scrutiny of the Catalent deal, Roche said it would use both in-house and external manufacturing for future commercial production of its obesity drugs.
Additional reporting by Maggie Fick in London, Editing by Rachel More, Tomasz Janowski, Mark Potter and David Evans
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
